CLINICAL & PIPELINE·Drug Approval
tobraDex: Decades of FDA Regulatory Management for a Type 3 New Dosage Form
The FDA's 1988 approval of tobraDex as a Type 3 New Dosage Form, application 50-616, highlights the enduring regulatory lifecycle of mature pharmaceutical products. Subsequent decades of supplemental approvals for labeling and manufacturing underscore critical ongoing compliance demands. This necessitates robust supply chain and regulatory strategies for long-standing market assets.
90-Day Activity